VIP in COVID: the primary outcome remains decisive
Study design: Humans; randomized study with 60-day follow-up
The research question
Some studies attract attention because of favorable subgroup results. For a careful assessment, it is important to first examine the outcome the study was designed to evaluate in advance.
What was found?
This study investigated intravenous aviptadil in severe COVID-related breathing problems. The primary outcome, being alive without respiratory failure on day 60, did not improve significantly from a statistical standpoint. The publication also contains favorable secondary or subgroup findings.
What does this evidence mean?
A secondary signal may justify further research, but it does not turn a non-significant primary outcome into convincing evidence. Discuss this publication together with TESICO. Both concern acute severe COVID and do not prove efficacy for long COVID.
Primary source
Research information, not medical advice. The study described does not establish the safe use of an investigational product. Image: AI illustration, not a participant or a photograph from the study.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.